Abstract
Rationale Asbestos is posited to cause otherwise ‘idiopathic’ pulmonary fibrosis (IPF); establishing this has important diagnostic and therapeutic implications.
Objectives To determine the association between occupational asbestos exposure and IPF; to investigate interaction with MUC5B rs35705950 genotype.
Methods Multi-centre, incident case-control study. Cases (n=494) were men diagnosed with IPF at 21 United Kingdom hospitals. Controls (n=466) were age-matched men who attended a hospital clinic in the same period. Asbestos exposure was measured using a validated job exposure matrix and a source-receptor model. The primary outcome was the association between asbestos exposure and IPF, estimated using logistic regression adjusted for age, smoking and centre. Interaction with MUC5B rs3570950 was investigated using a genetic dominant model.
Measurements and Main Results 327 (66%) cases and 293 (63%) controls ever had a high or medium asbestos exposure risk job; 8% of both cases and controls, had cumulative exposure estimates ≥ 25 fibre.ml−1.years. Occupational asbestos exposure was not associated with IPF, adjusted OR 1.1(95%CI 0.8-1.4; p=0.6) and there was no gene-environment interaction (p=0.2). Ever smoking was associated with IPF, OR 1.4 (95%CI 1-1.9; p=0.04). When stratifying for genotype there was significant interaction between smoking and work in an exposed job (p<0.01) for carriers of the minor allele of MUC5B rs3570950.
Conclusions Occupational asbestos exposure alone, or through interaction with MUC5B rs35705950 genotype, was not associated with IPF. However, exposure to asbestos and smoking interact to increase IPF risk in carriers of the minor allele of MUC5B rs3570950.
Clinical trial registered with www.clinicaltrials.gov (NCT03211507).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03211507
Clinical Protocols
Funding Statement
CJR was supported by Wellcome Trust clinical research training fellowship grant 201291/Z/16/Z.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the NHS Health Research Authority (IRAS project ID 203355, REC reference 17/EM/0021) and the sponsor was Imperial College London.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
All sources of support: CJR was supported by Wellcome Trust clinical research training fellowship grant 201291/Z/16/Z.
